Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|December 25, 2012
Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2)Joseph M G Nagano, Ku-Lung Hsu, Landon R Whitby, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 12, 2019
Stabilization of amyloidogenic immunoglobulin light chains by small moleculesGareth J Morgan, Nicholas L Yan, David E Mortenson, et al.
Journal of Gastroenterology and Hepatology|November 22, 2011
Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus MelbourneLani Prideaux, Michael A Kamm, Peter De Cruz, et al.
Elife|July 21, 2016
Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregationLars Plate, Christina B Cooley, John J Chen, et al.
ACS Chemical Biology|January 21, 2015
Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survivalJae Won Chang, Andrea M Zuhl, Anna E Speers, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposureEmma Flanagan, Peter R Gibson, Emily K Wright, et al.
Gastroenterology|April 12, 2016
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on InfectionMette Julsgaard, Lisbet A Christensen, Peter R Gibson, et al.
Journal of Gastroenterology and Hepatology|December 16, 2016
Serologic antibodies in relation to outcome in postoperative Crohn's diseaseAmy L Hamilton, Michael A Kamm, Peter De Cruz, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's DiseaseEmily K Wright, Michael A Kamm, Peter De Cruz, et al.
Pageof 6